Last reviewed · How we verify
NCT06617351
This Repeated Measures Parallel-group Investigation Will Examine the Influence of Short-term Melatonin Supplementation (5mg, 3 x Day for 72 Hours) on Cellular Responses, Functional Performance and Recovery Following an Acute Bout of Dynamic Resistance Exercise in Resistance Trained Men and Women
NA trial testing Melatonin in Cell Migration in 24 participants. Not yet recruiting.
31 March 2025
Quick facts
| Lead sponsor | University of Central Florida |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Enrollment | 24 |
| Start date | 1 October 2024 |
| Primary completion | 31 March 2025 |
| Estimated completion | 31 July 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Melatonin (MELATONIN) — full drug profile →
- Placebo
Conditions studied
- Cell Migration — all drugs for Cell Migration →
- Cell Invasion — all drugs for Cell Invasion →
- Exercise Recovery — all drugs for Exercise Recovery →
Sponsor
University of Central Florida
Who can join
Adults 18 to 40, any sex, with Cell Migration or Cell Invasion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Oral Melatonin is a commercially available product available alone and as a constituent in a number of supplements. Previous research suggests that short-term supplementation with oral melatonin may amplify the recovery response to damaging resistance exercise via modulation of subsequent immune and inflammatory responses. However the effects of oral melatonin on neutrophil and monocyte invasion/migration, a critical step in the resolution of skeletal muscle tissue homeostasis, has not been examined. An oral melatonin supplement (5mg) will be provided three times daily beginning 24-hours before and ending 48-hours after an acute bout of damaging resistance exercise (total 15mg/day for 3 days). Goals: 1. To investigate the effect of melatonin on systemic and cellular responses following an acute bout of damaging resistance exercise. 2. To investigate the effect of melatonin on measures of functional performance before and during recovery from an acute bout of damaging resistance exercise.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06617351
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Melatonin
Trials testing the same drug.
- NCT07221968 — Melatonin for the Treatment of DEE-SWAS · Phase 2 · not yet recruiting
- NCT07503600 — The Effect of Adjunctive Melatonin With Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections · Phase 3 · not yet recruiting
- NCT07375342 — Melatonin for Post Tonsillectomy Emergence Agitation in Pediatric · NA · enrolling by invitation
- NCT07305350 — EFFICACY OF MELATONIN IN MANAGEMENT OF HYPOXIC ISCHEMIC ENCEPHALOPATHY (HIE) IN NEONATES · Phase 2 · active not recruiting
- NCT07096635 — Oral Melatonin With Intra Articular Analgesia on Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction · NA · not yet recruiting
Other University of Central Florida trials
Trials by the same sponsor.
- NCT07203430 — Biopsychosocial Factors and Muscle Morphology After a Resistance Exercise · NA · completed
- NCT07214883 — UCF MammoChat: Image Repository · recruiting
- NCT06999057 — Quadriceps Motor Unit Adaptation to Simulated Knee Injury · NA · not yet recruiting
- NCT06979713 — Yoga, Education, and Nidra (YEN) for Chronic Low Back Pain: A Pilot Study on Pain Modulation, Well-Being, and Sleep · NA · not yet recruiting
- NCT06512168 — Measuring Aided Language Development · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06617351 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Central Florida
- Last refreshed: 1 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06617351.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing